Enzymatic ligation and other innovative technologies: Shaping the future of large-scale Oligonucleotide manufacturing

Oligonucleotide-based therapeutics are transforming modern medicine, offering targeted solutions for genetic disorders, cancer, cardiovascular disease, and CNS conditions. With more than 700 oligonucleotide drugs in the global pipeline and demand for large-scale production growing rapidly, manufacturing innovation is critical.

Traditional synthesis methods have provided a strong foundation but can face challenges with yield, scalability, and environmental sustainability, particularly for longer, chemically complex sequences. Approaches such as fragment synthesis and enzymatic ligation can address these challenges, delivering higher efficiency, greener processes, and greater flexibility in production.

Download our whitepaper to explore:

• The role of fragment synthesis with other innovations such as Stirred Bed Technology (SBT SPOS), and Tag-Assisted One-Pot Liquid Phase Oligonucleotide Synthesis (TOP LPOS) in enabling large-scale, sustainable manufacturing.
• Common applications, including siRNA, oligonucleotide conjugates, and complex molecular architectures.
• How enzymatic ligation improves cost efficiency, reduces chemical waste, and supports greener production processes.
• How Bachem’s enzymatic ligation processes routinely achieve >90–95% purity and higher overall yields.
• Bachem’s proven expertise in scaling oligonucleotide manufacturing from gram to multi-kilogram GMP production.

Unlock the future of oligonucleotide manufacturing and download the whitepaper today.